Drugs / Recombinant Botulinum Toxin Type A
Recombinant Botulinum Toxin Type A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07478822 | Mar 2026 → Jun 2027 expected | — | Chongqing Claruvis Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06583486 | Mar 2024 → Aug 2025 | — | Chongqing Claruvis Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant botulinum toxin type A | “multiple treatments with Recombinant Botulinum Toxin Type A for Injection (YY001) in the treatment of moderate to severe glabellar lines” NCT06583486 ↗ |
| Known as | Rcombinant botulinum neurotoxin type A | “Rcombinant botulinum neurotoxin type A for injection (YY001)” NCT06583486 ↗ |
| Known as | YY001 | “multiple treatments with Recombinant Botulinum Toxin Type A for Injection (YY001) in the treatment of moderate to severe glabellar lines” NCT06583486 ↗1“Recombinant botulinum toxin type A (YY001)” NCT07478822 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Recombinant botulinum toxin type A for injection (YY001)” NCT07478822 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT07478822 ↗ |